BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26545811)

  • 1. WSB1 promotes tumor metastasis by inducing pVHL degradation.
    Kim JJ; Lee SB; Jang J; Yi SY; Kim SH; Han SA; Lee JM; Tong SY; Vincelette ND; Gao B; Yin P; Evans D; Choi DW; Qin B; Liu T; Zhang H; Deng M; Jen J; Zhang J; Wang L; Lou Z
    Genes Dev; 2015 Nov; 29(21):2244-57. PubMed ID: 26545811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
    Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
    Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VBP1 represses cancer metastasis by enhancing HIF-1α degradation induced by pVHL.
    Kim JA; Choi DK; Min JS; Kang I; Kim JC; Kim S; Ahn JK
    FEBS J; 2018 Jan; 285(1):115-126. PubMed ID: 29121446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pVHL mediates K63-linked ubiquitination of nCLU.
    Xue J; Lv DD; Jiao S; Zhao W; Li X; Sun H; Yan B; Fan L; Hu RG; Fang J
    PLoS One; 2012; 7(4):e35848. PubMed ID: 22532874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis.
    Jung CR; Hwang KS; Yoo J; Cho WK; Kim JM; Kim WH; Im DS
    Nat Med; 2006 Jul; 12(7):809-16. PubMed ID: 16819549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP9X destabilizes pVHL and promotes cell proliferation.
    Zhang C; Peng Z; Zhu M; Wang P; Du X; Li X; Liu Y; Jin Y; McNutt MA; Yin Y
    Oncotarget; 2016 Sep; 7(37):60519-60534. PubMed ID: 27517496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage.
    Roe JS; Kim HR; Hwang IY; Cho EJ; Youn HD
    Oncogene; 2011 Jul; 30(28):3127-38. PubMed ID: 21358672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
    Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
    He X; Wang J; Messing EM; Wu G
    Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination.
    Jung JE; Kim HS; Lee CS; Shin YJ; Kim YN; Kang GH; Kim TY; Juhnn YS; Kim SJ; Park JW; Ye SK; Chung MH
    Exp Mol Med; 2008 Oct; 40(5):479-85. PubMed ID: 18985005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pVHL interacts with Ceramide kinase like (CERKL) protein and ubiquitinates it for oxygen dependent proteasomal degradation.
    Chen J; Liu F; Li H; Archacki S; Gao M; Liu Y; Liao S; Huang M; Wang J; Yu S; Li C; Tang Z; Liu M
    Cell Signal; 2015 Nov; 27(11):2314-23. PubMed ID: 26296657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of point mutations in pVHL on the binding of HIF-1α.
    Domene C; Illingworth CJ
    Proteins; 2012 Mar; 80(3):733-46. PubMed ID: 22105711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2.
    Okumura F; Joo-Okumura A; Nakatsukasa K; Kamura T
    PLoS One; 2017; 12(4):e0175593. PubMed ID: 28394947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
    Kaelin WG
    Cold Spring Harb Symp Quant Biol; 2005; 70():159-66. PubMed ID: 16869749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.
    Corn PG; McDonald ER; Herman JG; El-Deiry WS
    Nat Genet; 2003 Nov; 35(3):229-37. PubMed ID: 14556007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AK-1, a SIRT2 inhibitor, destabilizes HIF-1α and diminishes its transcriptional activity during hypoxia.
    Lee SD; Kim W; Jeong JW; Park JW; Kim JE
    Cancer Lett; 2016 Apr; 373(1):138-145. PubMed ID: 26808575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity.
    Li Z; Wang D; Na X; Schoen SR; Messing EM; Wu G
    EMBO J; 2003 Apr; 22(8):1857-67. PubMed ID: 12682018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of the von Hippel-Lindau tumor suppressor gene by late hypoxia limits HIF-1 expression.
    Karhausen J; Kong T; Narravula S; Colgan SP
    J Cell Biochem; 2005 Aug; 95(6):1264-75. PubMed ID: 15962286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The VHL tumor suppressor: master regulator of HIF.
    Haase VH
    Curr Pharm Des; 2009; 15(33):3895-903. PubMed ID: 19671042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.